

Robert Zeillinger

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/847708/robert-zeillinger-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

214
papers

7,034
citations

46
h-index

70
g-index

222
ext. papers

7,834
ext. citations

5
avg, IF

5.17
L-index

#	Paper	IF	Citations
214	The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer-A Study of the OVCAD Consortium. <i>Cancers</i> , 2021 , 13,	6.6	6
213	Patient satisfaction after breast cancer surgery : A prospective clinical trial. <i>Wiener Klinische Wochenschrift</i> , 2021 , 133, 6-13	2.3	5
212	Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer. <i>Investigational New Drugs</i> , 2021 , 1	4.3	1
211	tRNA-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression.. <i>Cancers</i> , 2021 , 14,	6.6	2
210	Gene Expression of Kallikreins in Breast Cancer Cell Lines. <i>Anticancer Research</i> , 2020 , 40, 2487-2495	2.3	1
209	miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients. <i>International Journal of Cancer</i> , 2020 , 147, 3560-3573	7.5	4
208	Definition and Independent Validation of a Proteomic-Classifer in Ovarian Cancer. <i>Cancers</i> , 2020 , 12,	6.6	2
207	miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. <i>Carcinogenesis</i> , 2020 , 41, 442-451	4.6	4
206	Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines. <i>Investigational New Drugs</i> , 2020 , 38, 946-955	4.3	3
205	Expression of Proteolytic Enzymes by Small Cell Lung Cancer Circulating Tumor Cell Lines. <i>Cancers</i> , 2019 , 11,	6.6	12
204	Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer. <i>Computational and Structural Biotechnology Journal</i> , 2019 , 17, 537-560	6.8	11
203	Molecular Characterization of Circulating Tumor Cells Enriched by A Microfluidic Platform in Patients with Small-Cell Lung Cancer. <i>Cells</i> , 2019 , 8,	7.9	15
202	Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan. <i>Cell Reports</i> , 2019 , 28, 132-144.e3	10.6	45
201	Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium. <i>Gynecologic Oncology</i> , 2018 , 149, 371-380	4.9	9
200	Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells. <i>Oncotarget</i> , 2018 , 9, 812-823	3.3	21
199	Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study. <i>International Journal of Gynecological Cancer</i> , 2018 , 28, 1692-1698	3.5	10
198	Polymer-Ligand-Based ELISA for Robust, High-Throughput, Quantitative Detection of p53 Aggregates. <i>Analytical Chemistry</i> , 2018 , 90, 13273-13279	7.8	8

197	Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer. <i>Frontiers in Pharmacology</i> , 2018 , 9, 842	5.6	3
196	Recommended Guidelines for Validation, Quality Control, and Reporting of Variants in Clinical Practice. <i>Cancer Research</i> , 2017 , 77, 1250-1260	10.1	45
195	Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer. <i>Oncology Letters</i> , 2017 , 13, 4047-4054	2.6	15
194	Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers. <i>PLoS ONE</i> , 2017 , 12, e0189641	3.7	4
193	Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. <i>Oncotarget</i> , 2017 , 8, 106415-106428	3.3	25
192	Small cell lung cancer: model of circulating tumor cell tumorspheres in chemoresistance. <i>Scientific Reports</i> , 2017 , 7, 5337	4.9	44
191	Comparison of a prototype reverse hybridization assay and MethyLight for detection of SFRP2 promotor methylation in fecal DNA. <i>International Journal of Biological Markers</i> , 2017 , 32, e467-e470	2.8	2
190	EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs. <i>Disease Markers</i> , 2017 , 2017, 9653194	3.2	30
189	PARP inhibition causes premature loss of cohesion in cancer cells. <i>Oncotarget</i> , 2017 , 8, 103931-103951	3.3	13
188	The 811 C/T polymorphism in the 3' untranslated region of the selenoprotein 15-kDa (Sep15) gene and breast cancer in Caucasian women. <i>Tumor Biology</i> , 2016 , 37, 1009-15	2.9	8
187	AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer. <i>BMC Genomics</i> , 2016 , 17, 643	4.5	11
186	Simple laboratory score improves the preoperative diagnosis of adnexal mass. <i>Tumor Biology</i> , 2016 , 37, 4343-9	2.9	6
185	Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. <i>European Journal of Cancer</i> , 2016 , 53, 51-64	7.5	33
184	Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype. <i>Cell Adhesion and Migration</i> , 2016 , 10, 360-7	3.2	33
183	Detection of circulating trophoblast particles in maternal blood using density gradient centrifugation in preeclampsia and in normotensive pregnancies. <i>Hypertension in Pregnancy</i> , 2016 , 35, 323-9	2	3
182	Association of HER2 codon 655 polymorphism with ovarian cancer. <i>Tumor Biology</i> , 2016 , 37, 7239-44	2.9	4
181	The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study. <i>Tumor Biology</i> , 2016 , 37, 3009-16	2.9	21
180	Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors. <i>Tumor Biology</i> , 2016 , 37, 12079-12087	2.9	11

179	Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium. <i>Anticancer Research</i> , 2016 , 36, 1015-22	2.3	4
178	Correlation of circular RNA abundance with proliferation--exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues. <i>Scientific Reports</i> , 2015 , 5, 8057	4.9	506
177	Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer. <i>Cancer Letters</i> , 2015 , 362, 218-28	9.9	17
176	Circulating tumor cells in small cell lung cancer: ex vivo expansion. <i>Lung</i> , 2015 , 193, 451-2	2.9	36
175	Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4293-300	2.2	57
174	Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome. <i>Oncotarget</i> , 2015 , 6, 17261-75	3.3	33
173	HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women. <i>Anticancer Research</i> , 2015 , 35, 5901-4	2.3	5
172	HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women. <i>Anticancer Research</i> , 2015 , 35, 6667-70	2.3	2
171	Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium. <i>Molecular Cancer</i> , 2014 , 13, 67	42.1	12
170	Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium. <i>European Journal of Cancer</i> , 2014 , 50, 99-110	7.5	39
169	Known players, new interplay in atherogenesis: Chronic shear stress and carbamylated-LDL induce and modulate expression of atherogenic LR11 in human coronary artery endothelium. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 323-32	7	6
168	HIF1 α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD Consortium. <i>OncoTargets and Therapy</i> , 2014 , 7, 1563-9	4.4	17
167	Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2014 , 135, 415-22	4.9	29
166	Association of myeloperoxidase with ovarian cancer. <i>Tumor Biology</i> , 2014 , 35, 141-8	2.9	31
165	Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. <i>Oncotarget</i> , 2014 , 5, 462-72	3.3	61
164	Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium. <i>Journal of Ovarian Research</i> , 2013 , 6, 42	5.5	32
163	A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium. <i>BMC Cancer</i> , 2013 , 13, 178	4.8	22
162	PP057. ENOS14 and EPHX1 polymorphisms affect maternal susceptibility to preeclampsia - Analysis of five polymorphisms predisposing to cardiovascular disease in 279 caucasian and 241 african women. <i>Pregnancy Hypertension</i> , 2013 , 3, 88	2.6	2

161	The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. <i>Gynecologic Oncology</i> , 2013 , 131, 15-20	4.9	79
160	Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium. <i>BMC Cancer</i> , 2013 , 13, 422	4.8	49
159	Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium. <i>Gynecologic Oncology</i> , 2013 , 128, 15-21	4.9	86
158	Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortium. <i>Gynecologic Oncology</i> , 2013 , 128, 38-43	4.9	16
157	Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. <i>Gynecologic Oncology</i> , 2013 , 128, 245-51	4.9	50
156	Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells. <i>International Journal of Oncology</i> , 2013 , 42, 1383-9	4.4	30
155	Association of TAP gene polymorphisms and risk of cervical intraepithelial neoplasia. <i>Disease Markers</i> , 2013 , 35, 79-84	3.2	19
154	Determination of tumor-infiltrating CD8+ lymphocytes in human ovarian cancer. <i>International Journal of Gynecological Pathology</i> , 2013 , 32, 269-76	3.2	7
153	The sulfatase pathway for estrogen formation: targets for the treatment and diagnosis of hormone-associated tumors. <i>Journal of Drug Delivery</i> , 2013 , 2013, 957605	2.3	33
152	Methylation status of TUSC3 is a prognostic factor in ovarian cancer. <i>Cancer</i> , 2013 , 119, 946-54	6.4	44
151	Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD. <i>International Journal of Gynecological Cancer</i> , 2013 , 23, 268-75	3.5	38
150	Duplex Reverse-Hybridization Assay for The Simultaneous Detection of KRAS/BRAF Mutations in FFPE-extracted Genomic DNA from Colorectal Cancer Specimens. <i>Disease Markers</i> , 2013 , 34, 171-177	3.2	7
149	The prostaglandine E2 transporting organic anion transporting polypeptide OATP4A1: A potential prognostic marker in colorectal cancer?. <i>Journal of Clinical Oncology</i> , 2013 , 31, 430-430	2.2	
148	Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium. <i>Cancer Science</i> , 2012 , 103, 1334-41	6.9	43
147	Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (. <i>European Journal of Cancer</i> , 2012 , 48, 2962-8	7.5	20
146	Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium. <i>Molecular Cancer</i> , 2012 , 11, 69	42.1	33
145	Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. <i>International Journal of Cancer</i> , 2012 , 131, E586-91	7.5	27
144	Relaxin and gonadal steroid receptors in uterosacral ligaments of women with and without pelvic organ prolapse. <i>International Urogynecology Journal</i> , 2012 , 23, 495-500	2	11

143	MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer. <i>Oncology Reports</i> , 2012 , 27, 673-7	3.5	4
142	Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF- κ B activation. <i>Annals of Oncology</i> , 2012 , 23, 1795-802	10.3	53
141	A Miniaturized Ligand Binding Assay for EGFR. <i>International Journal of Proteomics</i> , 2012 , 2012, 247059		1
140	Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. <i>International Journal of Gynecological Cancer</i> , 2012 , 22, 380-5	3.5	67
139	Anticancer effects of the organosilicon multidrug resistance modulator SILA 421. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012 , 12, 663-71	2.2	3
138	The N-terminally truncated p53 isoform Δ 0p53 influences prognosis in mucinous ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2012 , 22, 372-9	3.5	30
137	Use of HE4 and CA125 to predict surgical outcome and for prognostic value for progression-free survival (PFS) and overall survival (OS) in primary epithelial ovarian cancer (EOC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5034-5034	2.2	
136	Interval versus primary tumor debulking surgery in advanced ovarian cancer: Analysis of the European OVCAD data.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5071-5071	2.2	1
135	Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. <i>Biomedicine and Pharmacotherapy</i> , 2011 , 65, 417-26	7.5	60
134	KRAS mutation analysis in genomic DNA isolated from formalin-fixed paraffin-embedded ovarian tissue: evaluation of a strip-based reverse-hybridisation assay. <i>Journal of Clinical Pathology</i> , 2011 , 64, 252-6	3.9	7
133	Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer. <i>Oncology Reports</i> , 2011 , 26, 1037-45	3.5	25
132	Genetic variations of interleukin-1 and -6 genes and risk of cervical intraepithelial neoplasia. <i>Gynecologic Oncology</i> , 2011 , 121, 537-41	4.9	24
131	Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. <i>Acta Oncologica</i> , 2011 , 50, 700-10	3.2	186
130	Anticancer activity and mode of action of titanocene C. <i>Investigational New Drugs</i> , 2011 , 29, 607-14	4.3	20
129	Expression of p16 protein and epidermal growth factor receptor in patients with adenocarcinoma of the uterine cervix: an immunohistochemical analysis. <i>Archives of Gynecology and Obstetrics</i> , 2011 , 283, 611-6	2.5	5
128	Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept. <i>Cytometry Part B - Clinical Cytometry</i> , 2011 , 80, 100-11	3.4	53
127	Δ 33p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. <i>British Journal of Cancer</i> , 2011 , 105, 1593-9	8.7	31
126	Clinical relevance of TAp73 and Δ p73 protein expression in ovarian cancer: a series of 83 cases and review of the literature. <i>International Journal of Gynecological Pathology</i> , 2011 , 30, 527-31	3.2	8

125	hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 7816-27	12.9	32
124	A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 850-60	6.1	52
123	Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients. <i>Cancer Investigation</i> , 2011 , 29, 180-6	2.1	3
122	Biochip-based detection of KRAS mutation in non-small cell lung cancer. <i>International Journal of Molecular Sciences</i> , 2011 , 12, 8530-8	6.3	4
121	Association of C-reactive protein (CRP) gene polymorphisms, serum CRP levels and cervical cancer prognosis. <i>Anticancer Research</i> , 2011 , 31, 2259-64	2.3	17
120	Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. <i>Oncogene</i> , 2010 , 29, 1997-2004	9.2	60
119	Genome-wide gene expression analysis of chemoresistant pulmonary carcinoid cells. <i>Lung Cancer: Targets and Therapy</i> , 2010 , 1, 107-117	2.9	2
118	New and potential clinical applications of KRAS as a cancer biomarker. <i>Expert Opinion on Medical Diagnostics</i> , 2010 , 4, 383-95		5
117	Circulating tumor cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods. <i>Cancer Letters</i> , 2010 , 293, 117-23	9.9	44
116	Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. <i>BMC Cancer</i> , 2010 , 10, 666	4.8	78
115	Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients. <i>BMC Cancer</i> , 2010 , 10, 682	4.8	19
114	ABC transporter gene expression in benign and malignant ovarian tissue. <i>Gynecologic Oncology</i> , 2010 , 117, 198-201	4.9	39
113	BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-beta treatment. <i>Gynecologic Oncology</i> , 2010 , 117, 189-97	4.9	35
112	Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters. <i>Anticancer Research</i> , 2010 , 30, 1341-5 ²⁻³		27
111	In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent. <i>Metal-Based Drugs</i> , 2009 , 2009, 348916		20
110	KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. <i>BMC Cancer</i> , 2009 , 9, 111	4.8	72
109	The prognostic value of four interleukin-1 gene polymorphisms in Caucasian women with breast cancer: a multicenter study. <i>BMC Cancer</i> , 2009 , 9, 78	4.8	12
108	A prognostic gene expression index in ovarian cancer - validation across different independent data sets. <i>Journal of Pathology</i> , 2009 , 218, 273-80	9.4	80

107	Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. <i>Journal of Molecular Diagnostics</i> , 2009 , 11, 508-13	5.1	32
106	Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents. <i>Anti-Cancer Drugs</i> , 2009 , 20, 559-72	2.4	16
105	The prohibitin 3 untranslated region polymorphism in patients with ovarian cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2008 , 137, 236-9	2.4	7
104	Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 710-4	12.9	149
103	Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring. <i>Disease Markers</i> , 2008 , 25, 159-65	3.2	46
102	Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 898-901	12.9	93
101	In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway. <i>British Journal of Cancer</i> , 2007 , 96, 485-91	8.7	63
100	Vascular endothelial growth factor gene polymorphisms in ovarian cancer. <i>Gynecologic Oncology</i> , 2007 , 105, 385-9	4.9	26
99	The neuronal guidance cue Slit2 induces targeted migration and may play a role in brain metastasis of breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2007 , 106, 333-42	4.4	78
98	Oncogenic BARD1 isoforms expressed in gynecological cancers. <i>Cancer Research</i> , 2007 , 67, 11876-85	10.1	50
97	p16INK4a expression in invasive vulvar squamous cell carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2007 , 15, 279-83	1.9	26
96	The lack of laminin-5 as a prognostic marker in low-grade cervical squamous intraepithelial lesions: correlation with clinical follow-up data. <i>International Journal of Gynecological Pathology</i> , 2007 , 26, 89-94 ^{3,2}	3	3
95	Expression of the human MTA1 gene in breast cell lines and in breast cancer tissues. <i>Oncology Research</i> , 2007 , 16, 465-70	4.8	10
94	Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study. <i>Anticancer Research</i> , 2007 , 27, 1527-30	2.3	6
93	The -463G/A polymorphism in myeloperoxidase gene and cervical cancer. <i>Anticancer Research</i> , 2007 , 27, 1531-5	2.3	9
92	A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2006 , 100, 506-10	4.9	22
91	Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. <i>Gynecologic Oncology</i> , 2006 , 103, 512-7	4.9	117
90	Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 2442-8	12.9	88

89	Genotype distribution of estrogen receptor-alpha, catechol-O-methyltransferase, and cytochrome P450 17 gene polymorphisms in Caucasian women with uterine leiomyomas. <i>Fertility and Sterility</i> , 2006 , 85, 462-7	4.8	33
88	Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006 , 98, 151-5	4.4	34
87	A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the presence of polycystic ovary syndrome in Caucasian women. <i>Fertility and Sterility</i> , 2005 , 83, 1565-7	4.8	8
86	Polymorphisms of the Nos3 gene and unexplained late intrauterine fetal death. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2005 , 122, 151-5	2.4	5
85	Biochip for K-ras mutation screening in ovarian cancer. <i>Clinical Chemistry</i> , 2005 , 51, 784-7	5.5	15
84	HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. <i>Oncology Reports</i> , 2005 , 14, 737	3.5	1
83	Polymorphisms within the interleukin-1 gene family and unexplained late intrauterine fetal death: a multi-center study. <i>American Journal of Reproductive Immunology</i> , 2005 , 53, 132-5	3.8	4
82	An Angiopoietin-2 gene polymorphism in unexplained intrauterine fetal death: a multi-center study. <i>Journal of Reproductive Immunology</i> , 2005 , 65, 47-53	4.2	4
81	Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer. <i>Gynecologic Oncology</i> , 2005 , 97, 514-8	4.9	17
80	The use of a panel of monoclonal antibodies to enrich circulating breast cancer cells facilitates their detection. <i>Gynecologic Oncology</i> , 2005 , 98, 211-6	4.9	29
79	Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. <i>Cancer</i> , 2005 , 104, 2417-29	6.4	81
78	Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens. <i>Oncology Reports</i> , 2005 , 13, 375	3.5	4
77	Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. <i>Clinical Cancer Research</i> , 2005 , 11, 8585-91	12.9	52
76	Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. <i>Molecular Cancer Research</i> , 2005 , 3, 335-43	6.6	123
75	An interleukin-6 gene promoter polymorphism and unexplained late intrauterine fetal death: a multicenter study. <i>Journal of the Society for Gynecologic Investigation</i> , 2005 , 12, 33-6		4
74	Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. <i>Clinical Cancer Research</i> , 2005 , 11, 8372-83	12.9	78
73	Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women. <i>Clinical Cancer Research</i> , 2005 , 11, 5718-21	12.9	88
72	A common interleukin-6 promoter polymorphism in patients with vulvar cancer. <i>Journal of the Society for Gynecologic Investigation</i> , 2005 , 12, 617-20		12

71	Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens. <i>Oncology Reports</i> , 2005 , 13, 375-87	3.5	37
70	Identification of CRASH, a gene deregulated in gynecological tumors 2004 , 24, 33		2
69	Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. <i>Cancer Research</i> , 2004 , 64, 2449-60	10.1	121
68	A polymorphism of the interleukin-1 receptor antagonist plays a prominent role within the interleukin-1 gene cluster in vulvar carcinogenesis. <i>Gynecologic Oncology</i> , 2004 , 92, 936-40	4.9	19
67	Polymorphisms of the endothelial nitric oxide synthase gene in women with vulvar cancer. <i>Gynecologic Oncology</i> , 2004 , 93, 686-90	4.9	32
66	Loss of heterozygosity on chromosome 13q: suggestion of a candidate tumor suppressor gene in sporadic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2004 , 83, 143-8	4.4	6
65	CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia. <i>Breast Cancer Research and Treatment</i> , 2004 , 84, 247-50	4.4	66
64	Genetic polymorphisms associated with thrombophilia and vascular disease in women with unexplained late intrauterine fetal death: a multicenter study. <i>Journal of the Society for Gynecologic Investigation</i> , 2004 , 11, 42-4		38
63	A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2004 , 81, 1638-41	4.8	36
62	Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response. <i>Oncology Reports</i> , 2004 , 11, 1281-6	3.5	14
61	Role of p53 in G2/M cell cycle arrest and apoptosis in response to irradiation in ovarian carcinoma cell lines 2003 , 22, 51		
60	Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer 2003 , 22, 1117		3
59	Rad52 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients. <i>Oncology Reports</i> , 2003 , 10, 1551	3.5	
58	The mouse mammary tumor virus-like env gene sequence is not detectable in breast cancer tissue of Austrian patients. <i>Oncology Reports</i> , 2003 , 10, 1025	3.5	8
57	Evaluation of MUC1 splice variants as prognostic markers in patients with ductal carcinoma in situ of the breast. <i>Oncology Reports</i> , 2003 , 10, 1981	3.5	
56	Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines. <i>Breast Cancer Research and Treatment</i> , 2003 , 79, 37-46	4.4	44
55	Identification of genes associated with the invasive status of human mammary carcinoma cell lines by transcriptional profiling. <i>Tumor Biology</i> , 2003 , 24, 189-98	2.9	31
54	Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines. <i>International Journal of Oncology</i> , 2003 , 22, 51-7	1	13

53	Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells. <i>Oncology Reports</i> , 2003 , 10, 405-10	3.5	26
52	The mouse mammary tumor virus-like env gene sequence is not detectable in breast cancer tissue of Austrian patients. <i>Oncology Reports</i> , 2003 , 10, 1025-9	3.5	36
51	An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. <i>Cancer Research</i> , 2003 , 63, 3066-8	10.1	65
50	Expression profiling of mammary carcinoma cell lines: correlation of in vitro invasiveness with expression of CD24. <i>Tumor Biology</i> , 2002 , 23, 139-45	2.9	49
49	Expression of MUC1 splice variants in benign and malignant ovarian tumours. <i>International Journal of Cancer</i> , 2002 , 100, 166-71	7.5	36
48	No association between the human progesterone receptor gene polymorphism PROGINS and risk for ovarian carcinoma in Austrian women. <i>International Journal of Cancer</i> , 2002 , 101, 203-203	7.5	3
47	Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer. <i>Gynecologic Oncology</i> , 2002 , 86, 134-7	4.9	47
46	Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines. <i>Breast Cancer Research and Treatment</i> , 2002 , 71, 249-55	4.4	72
45	Human progesterone receptor gene polymorphism PROGINS and risk for breast cancer in Austrian women. <i>Breast Cancer Research and Treatment</i> , 2002 , 72, 131-7	4.4	21
44	Expression of MUC1 splice variants correlates with invasive growth of breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 2002 , 76, 211-9	4.4	11
43	Polymorphisms of the angiotensinogen gene, the endothelial nitric oxide synthase gene, and the interleukin-1beta gene promoter in women with idiopathic recurrent miscarriage. <i>Molecular Human Reproduction</i> , 2002 , 8, 95-100	4.4	43
42	Polymorphisms of the Interleukin-1 Gene Cluster and Ovarian Cancer. <i>Journal of the Society for Gynecologic Investigation</i> , 2002 , 9, 386-390		15
41	Genetic alterations in endometrial hyperplasia and cancer. <i>Cancer Letters</i> , 2002 , 175, 205-11	9.9	18
40	Basal expression of the multidrug resistance gene 1 (MDR-1) is associated with the TT genotype at the polymorphic site C3435T in mammary and ovarian carcinoma cell lines. <i>Cancer Letters</i> , 2002 , 185, 79-85	9.9	25
39	Tumor necrosis factor-alpha promoter polymorphisms and endometriosis. <i>Journal of the Society for Gynecologic Investigation</i> , 2002 , 9, 313-8		27
38	Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. <i>Clinical Cancer Research</i> , 2002 , 8, 2253-9	12.9	53
37	Analysis of the human progesterone receptor gene polymorphism progins in Austrian ovarian carcinoma patients. <i>International Journal of Cancer</i> , 2001 , 95, 394-7	7.5	37
36	Novel MUC1 splice variants are expressed in cervical carcinoma. <i>Gynecologic Oncology</i> , 2001 , 83, 343-7	4.9	26

35	High frequency of allelic imbalance at regions of chromosome arm 8p in ovarian carcinoma. <i>Cancer Genetics and Cytogenetics</i> , 2001 , 129, 23-9		33
34	Endothelial nitric oxide synthase gene polymorphism in women with idiopathic recurrent miscarriage. <i>Human Reproduction</i> , 2001 , 16, 1644-7	5.7	60
33	Loss of heterozygosity (LOH) at p53 is correlated with LOH at BRCA1 and BRCA2 in various human malignant tumors. <i>International Journal of Cancer</i> , 2000 , 88, 319-22	7.5	17
32	Detection of p53 Polymorphism at Codon 72 by PCR and Allele-specific Oligonucleotide Hybridization on Microtiter Plates. <i>Clinical Chemistry</i> , 2000 , 46, 124-126	5.5	7
31	p53-dependent radioresistance in ovarian carcinoma cell lines. <i>Cancer Letters</i> , 2000 , 150, 191-9	9.9	26
30	BRCA1 Gene Mutations in Sporadic Ovarian Carcinomas: Detection by PCR and Reverse Allele-specific Oligonucleotide Hybridization. <i>Clinical Chemistry</i> , 1999 , 45, 976-981	5.5	30
29	Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 1999 , 56, 91-7	4.4	45
28	Expression of mucins and cytokeratins in ovarian cancer cell lines. <i>Cancer Letters</i> , 1999 , 145, 133-41	9.9	24
27	Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. <i>British Journal of Cancer</i> , 1998 , 77, 1870-4	8.7	52
26	A differential PCR system for the determination of CCND1 (Cyclin D1) gene amplification in head and neck squamous cell carcinomas. <i>Oral Oncology</i> , 1998 , 34, 257-260	4.4	10
25	Cytosol concentrations of CD44 isoforms in breast cancer tissue. <i>International Journal of Cancer</i> , 1998 , 79, 541-5	7.5	10
24	Chromosome region 8p11-p21: refined mapping and molecular alterations in breast cancer. <i>Genes Chromosomes and Cancer</i> , 1998 , 22, 186-99	5	53
23	Influence of intratumoral basic fibroblast growth factor concentration on survival in ovarian cancer patients. <i>Cancer Letters</i> , 1998 , 130, 69-76	9.9	31
22	Tissue expression and serum levels of HER-2/neu in patients with breast cancer. <i>Oncology</i> , 1997 , 54, 475-81	9.9	66
21	Estrogen does not induce the calcium-dependent nitric oxide synthase in cultured human uterine endothelial and myometrial smooth muscle cells. <i>Journal of Vascular Research</i> , 1997 , 34, 281-8	1.9	17
20	Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma. <i>International Journal of Cancer</i> , 1997 , 74, 322-5	7.5	19
19	Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. <i>International Journal of Cancer</i> , 1997 , 74, 455-8	7.5	111
18	Quantitative determination of gene expression by competitive reverse transcription-polymerase chain reaction in degraded RNA samples. <i>Analytical Biochemistry</i> , 1997 , 251, 173-7	3.1	27

17	PCR-mediated synthesis of exogenous competitors for quantitative RT-PCR. <i>BioTechniques</i> , 1996 , 20, 360-2	2.5	12
16	Presence of endothelial calcium-dependent nitric oxide synthase in breast apocrine metaplasia. <i>British Journal of Cancer</i> , 1996 , 74, 1423-6	8.7	22
15	Simultaneous expression of nitric oxide synthase and estrogen receptor in human breast cancer cell lines. <i>Breast Cancer Research and Treatment</i> , 1996 , 40, 205-7	4.4	41
14	Quantification of uPA receptor expression in human breast cancer cell lines by cRT-PCR. <i>Breast Cancer Research and Treatment</i> , 1996 , 40, 257-63	4.4	14
13	Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. <i>International Journal of Cancer</i> , 1996 , 69, 247-53	7.5	138
12	Association of allelic losses on human chromosomal arms 11Q and 16Q in sporadic breast cancer. <i>International Journal of Cancer</i> , 1996 , 69, 307-11	7.5	10
11	DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours. <i>British Journal of Cancer</i> , 1996 , 74, 1984-9	8.7	61
10	Fetal fibronectin as a marker to predict the onset of term labor and delivery. <i>American Journal of Obstetrics and Gynecology</i> , 1995 , 172, 134-7	6.4	37
9	Fetal fibronectin as a selection criterion for induction of term labor. <i>American Journal of Obstetrics and Gynecology</i> , 1995 , 173, 1513-7	6.4	37
8	Quantitative detection of reverse transcriptase-PCR products by means of a novel and sensitive DNA stain. <i>Genome Research</i> , 1995 , 4, 234-8	9.7	156
7	Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study. <i>British Journal of Cancer</i> , 1995 , 71, 1292-6	8.7	40
6	Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer. <i>Genes Chromosomes and Cancer</i> , 1994 , 9, 42-8	5	79
5	Patterns of allele losses suggest the existence of five distinct regions of LOH on chromosome 17 in breast cancer. <i>International Journal of Cancer</i> , 1994 , 56, 193-9	7.5	63
4	HER-2 oncogene amplification and overall survival of breast carcinoma patients. <i>European Journal of Cancer & Clinical Oncology</i> , 1990 , 26, 946-9		15
3	Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells. <i>Oncology Reports</i> ,	3.5	2
2	Ultra-Sensitive Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue Over a Century of Human Lifespan. <i>SSRN Electronic Journal</i> ,	1	1
1	Ultra-sensitive sequencing for cancer detection reveals progressive clonal selection in normal tissue over a century of human lifespan		1